A. Johnston

A Novel Autotaxin Inhibitor Reduces Lysophosphatidic Acid Levels in Plasma and the Site of Inflammation

J. Gierse, J. Masferrer, A. Wittwer, 2010, Journal of Pharmacology and Experimental Therapeutics.

Phase I studies with the nonclassical antifolate nolatrexed dihydrochloride (AG337, THYMITAQ) administered orally for 5 days.

A. Boddy, D. Newell, A. Johnston, 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase I study of the lipophilic thymidylate synthase inhibitor Thymitaq™ (nolatrexed dihydrochloride) given by 10-day oral administration

A. Boddy, A. Johnston, D. Jodrell, 1999, British Journal of Cancer.

Clinical pharmacokinetic and in vitro combination studies of nolatrexed dihydrochloride (AG337, ThymitaqTM) and paclitaxel

A. Boddy, D. Newell, A. Johnston, 2000, British Journal of Cancer.

Thymidylate Synthase

A. Boddy, A. Johnston, D. Jodrell, 2022 .

Intravenous Parecoxib Rapidly Leads to COX‐2 Inhibitory Concentration of Valdecoxib in the Central Nervous System

A. Johnston, A. Bello, R. Cheung, 2008, Clinical pharmacology and therapeutics.

A phase I study of nolatrexed dihydrochloride in children with advanced cancer. A United Kingdom Children's Cancer Study Group Investigation

A. Boddy, I. Lewis, B. Morland, 2001, British Journal of Cancer.

Phase I trial of the thymidylate synthase inhibitor AG331 as a 5-day continuous infusion.

P. O'dwyer, J. Gallo, A. Johnston, 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.